Applied Therapeutics (NASDAQ:APLT) & Genprex (NASDAQ:GNPX) Financial Analysis

Applied Therapeutics (NASDAQ:APLT) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Applied Therapeutics and Genprex, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1	2	0	0	1.67
Genprex	1	0	0	0	1.00

Applied Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Applied Therapeutics is more favorable than Genprex.

Profitability

This table compares Applied Therapeutics and Genprex’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Genprex	N/A	-247.32%	-176.73%

Valuation and Earnings

This table compares Applied Therapeutics and Genprex”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1.00 million	15.86	-$105.62 million	($0.10)	-1.03
Genprex	N/A	N/A	-$16.23 million	($14.14)	-0.06

Genprex has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, Genprex has a beta of -0.94, suggesting that its share price is 194% less volatile than the S&P 500.

Insider & Institutional Ownership

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Genprex shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 0.3% of Genprex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Applied Therapeutics beats Genprex on 8 of the 11 factors compared between the two stocks.

About Applied Therapeutics

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

About Genprex

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.